{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:21:12Z","timestamp":1788870072028,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Universidad de la Rep\u00fablica (Uruguay)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.autrev.2013.10.013","type":"journal-article","created":{"date-parts":[[2013,11,2]],"date-time":"2013-11-02T00:45:44Z","timestamp":1383353144000},"page":"206-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Prednisone in lupus nephritis: How much is enough?"],"prefix":"10.1016","volume":"13","author":[{"given":"Guillermo","family":"Ruiz-Irastorza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Danza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irama","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munther","family":"Khamashta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2013.10.013_bb0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00005792-199905000-00002","article-title":"Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center","volume":"78","author":"Huong","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2013.10.013_bb0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2013.10.013_bb0015","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2013.10.013_bb0020","first-page":"1","article-title":"Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.)","volume":"32","author":"Ruiz Irastorza","year":"2012","journal-title":"Nefrologia"},{"key":"10.1016\/j.autrev.2013.10.013_bb0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/0961203306075614","article-title":"Current management of lupus nephritis: popular misconceptions","volume":"16","author":"Jayne","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2013.10.013_bb0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0272-6386(97)90029-9","article-title":"Treatment of lupus nephritis: a meta-analysis of clinical trials","volume":"29","author":"Bansal","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2013.10.013_bb0035","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis","volume":"343","author":"Chan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.10.013_bb0040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2013.10.013_bb0045","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.10.013_bb0050","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/ard.2002.003574","article-title":"EULAR randomized controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophsphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis","volume":"63","author":"Yee","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.10.013_bb0055","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis","volume":"350","author":"Contreras","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.10.013_bb0060","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.10.013_bb0065","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2013.10.013_bb0070","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/acr.20139","article-title":"Reporting of corticosteroid use in systemic disease trials: evidence from a systematic review of the potential impact on treatment effect","volume":"62","author":"Pagnaux","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2013.10.013_bb0075","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.10.013_bb0080","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.10.013_bb0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2013.10.013_bb0090","first-page":"9","article-title":"Induction and maintenance therapy in proliferative lupus nephritis","volume":"23","author":"Ponticelli","year":"2010","journal-title":"J Nephrol"},{"key":"10.1016\/j.autrev.2013.10.013_bb0095","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2012.08.018","article-title":"Lupus nephritis: a critical review","volume":"12","author":"Borchers","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.10.013_bb0100","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.autrev.2012.12.002","article-title":"Long-term complications of past glucocorticoid use","volume":"12","author":"Seguro","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.10.013_bb0105","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1002\/art.20583","article-title":"Glucocorticoids in the treatment of rheumatic diseases. An update on the mechanisms of action","volume":"50","author":"Buttgereit","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.10.013_bb0110","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ncprheum0898","article-title":"Genomic and nongenomic effects of glucocorticoids","volume":"4","author":"Stahn","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.autrev.2013.10.013_bb0115","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/ker410","article-title":"Glucocorticoid use and abuse in SLE","volume":"51","author":"Ruiz-Irastorza","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.10.013_bb0120","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0140-6736(05)71005-9","article-title":"Optimised glucocorticoid therapy: the sharpening of an old spear","volume":"365","author":"Buttgereit","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2013.10.013_bb0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low doses glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.10.013_bb0130","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.10.013_bb0135","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic lupus erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.10.013_bb0140","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O","article-title":"Damage in systemic lupus erythematosus and its association with corticosteroids","volume":"43","author":"Zonana-Nacach","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.10.013_bb0145","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3899\/jrheum.080828","article-title":"Prednisone, lupus activity, and permanent organ damage","volume":"36","author":"Thamer","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.10.013_bb0150","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2764","article-title":"Aguirre predictors of major infections in systemic lupus erythematosus","volume":"11","author":"Ruiz-Irastorza","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2013.10.013_bb0155","first-page":"483","article-title":"Effects of low or medium-dose of prednisone on insulin resistance in patients with systemic lupus erythematosus","volume":"28","author":"Sabio","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2013.10.013_bb0160","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3899\/jrheum.120537","article-title":"Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study","volume":"39","author":"Fischer-Betz","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.10.013_bb0165","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.10.013_bb0170","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1093\/ndt\/gfp336","article-title":"Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids","volume":"24","author":"Pepper","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2013.10.013_bb0175","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/art.24538","article-title":"Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort","volume":"61","author":"Pons-Estel","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.10.013_bb0180","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1191\/0961203306lu2271oa","article-title":"Sustained remission of lupus nephritis","volume":"15","author":"Barber","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2013.10.013_bb0185","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1191\/0961203306lu2313oa","article-title":"Hydroxychloroquine use predicts complete renal remission within 12month among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis","volume":"15","author":"Kasitanon","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2013.10.013_bb0190","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2013.10.013_bb0195","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.10.013_bb0200","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1002\/art.20666","article-title":"Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial","volume":"50","author":"Houssiau","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.10.013_bb0205","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.10.013_bb0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.autrev.2010.08.014","article-title":"SLE diagnosis and treatment: when early is early","volume":"10","author":"Doria","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.10.013_bb0215","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1094-5539(03)00104-4","article-title":"Corticosteroid use and its association with microalbuminuria in the adult population","volume":"16","author":"Monster","year":"2003","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.autrev.2013.10.013_bb0220","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1939-1676.2007.0039.x","article-title":"The effects of hydrocortisone on systemic arterial blood pressure and urinary protein excretion in dogs","volume":"22","author":"Schellenberg","year":"2008","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.autrev.2013.10.013_bb0225","first-page":"37","article-title":"Effects of glucocorticoid administration on urinary albumin excretion by the normal kidney","volume":"4","author":"Zager","year":"1981","journal-title":"Ren Physiol"},{"key":"10.1016\/j.autrev.2013.10.013_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygcen.2010.07.004","article-title":"Cushing's syndrome, glucocorticoids and the kidney","volume":"169","author":"Smets","year":"2010","journal-title":"Gen Comp Endocrinol"},{"key":"10.1016\/j.autrev.2013.10.013_bb0235","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0307-742X(21)00214-9","article-title":"The treatment of SLE: the case for conservative management","volume":"8","author":"Hughes","year":"1982","journal-title":"Clin Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997213002061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997213002061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T08:42:17Z","timestamp":1646988137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997213002061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1568997213002061"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2013.10.013","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prednisone in lupus nephritis: How much is enough?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2013.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}